Redhill Biopharma Ltd. (RDHL)

Price$1.00

Value ScoreA

Growth ScoreF

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-19.78%

Price vs S&P 500 (4W)-12.81%

VGM Score45.68

Market Capitalization$5.19M

All Metrics

Book Value / Share (Quarterly)$0.00

P/TBV (Annual)4.90x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-83.34%

Cash Flow / Share (Quarterly)$-0.00

Price vs S&P 500 (YTD)-13.85%

Gross Margin (TTM)60.41%

Net Profit Margin (TTM)-104.51%

EPS (TTM)$-0.00

10-Day Avg Trading Volume0.15M

EPS Excl Extra (TTM)$-0.00

Revenue Growth (5Y)-66.15%

EPS (Annual)$0.00

ROI (Annual)-8.04%

Gross Margin (Annual)60.31%

Net Profit Margin (5Y Avg)-23.30%

Cash / Share (Quarterly)$0.00

Revenue Growth QoQ (YoY)-96.44%

ROA (Last FY)-1.69%

Revenue Growth TTM (YoY)-58.88%

EBITD / Share (TTM)$-0.00

ROE (5Y Avg)-114.16%

Operating Margin (TTM)-282.25%

Cash Flow / Share (Annual)$-0.00

P/B Ratio1.22x

P/B Ratio (Quarterly)1.10x

Net Income / Employee (Annual)$-12,300

EV / Revenue (TTM)0.52x

Net Interest Coverage (TTM)4.20x

ROA (TTM)-20.87%

EV / EBITDA (TTM)0.46x

EPS Incl Extra (Annual)$0.00

Current Ratio (Annual)0.34x

Quick Ratio (Quarterly)0.21x

3-Month Avg Trading Volume0.06M

52-Week Price Return-43.18%

Revenue / Employee (TTM)$124,700

Tangible BV / Share (Quarterly)$0.01

P/S Ratio (Annual)18.15x

Asset Turnover (Annual)0.01x

52-Week High$3.31

Operating Margin (5Y Avg)-522.77%

EPS Excl Extra (Annual)$0.00

CapEx CAGR (5Y)-84.38%

Tangible BV CAGR (5Y)13.88%

26-Week Price Return-3.85%

Quick Ratio (Annual)0.21x

13-Week Price Return2.04%

Total Debt / Equity (Annual)0.25x

Current Ratio (Quarterly)0.34x

Enterprise Value$2.29M

Revenue / Share Growth (5Y)-49.45%

Asset Turnover (TTM)0.20x

Book Value / Share Growth (5Y)-77.68%

Revenue / Employee (Annual)$8,200

Inventory Turnover (Annual)0.79x

Pretax Margin (Annual)-2825.17%

Cash / Share (Annual)$0.00

3-Month Return Std Dev66.32%

Gross Margin (5Y Avg)50.01%

Net Income / Employee (TTM)$-130,300

ROE (Last FY)-10.05%

Net Interest Coverage (Annual)-46.25x

EPS Basic Excl Extra (Annual)$0.00

Receivables Turnover (TTM)3.33x

EV / Free Cash Flow (TTM)-0.02x

Total Debt / Equity (Quarterly)0.25x

EPS Incl Extra (TTM)$-0.00

Receivables Turnover (Annual)0.22x

ROI (TTM)-8.04%

P/S Ratio (TTM)1.19x

Pretax Margin (5Y Avg)-558.33%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.01

Price vs S&P 500 (52W)-71.39%

Year-to-Date Return-2.91%

5-Day Price Return2.06%

EPS Normalized (Annual)$0.00

ROA (5Y Avg)-8.56%

Net Profit Margin (Annual)-150.00%

Month-to-Date Return-8.26%

Cash Flow / Share (TTM)$31.18

EBITD / Share (Annual)$-0.00

Operating Margin (Annual)-2776.92%

LT Debt / Equity (Annual)9.39x

ROI (5Y Avg)97.34%

LT Debt / Equity (Quarterly)9.39x

EPS Basic Excl Extra (TTM)$-0.00

P/TBV (Quarterly)5.75x

P/B Ratio (Annual)1.10x

Inventory Turnover (TTM)1.38x

Pretax Margin (TTM)-279.79%

Book Value / Share (Annual)$0.00

Price vs S&P 500 (13W)-7.71%

Beta5.07x

Revenue / Share (TTM)$0.00

ROE (TTM)-10.05%

52-Week Low$0.71

vGradeA

gGradeF

mGradeC

vgmGradeC

Show chart for

Analyst Recommendations

Dec 2024

Jan 2025

Feb 2025

Mar 2025

4.14

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
RDHLRedhill Biopharma Ltd.	A	F	C	$1.00
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Redhill Biopharma is a specialty biopharmaceutical company focused on gastrointestinal diseases, with commercialized products Talicia and Aemcolo available in the U.S. market. The company maintains a clinical-stage pipeline of five therapeutic candidates, including Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, primarily in clinical development.